OssDsign
OssDsign publishes Annual Report 2024
“Despite operating in a highly competitive market, we have shown there are vast growth opportunities when offering state-of-the-art innovation that solves the clinical challenges” said Morten Henneveld, CEO, OssDsign AB.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com
Certified Adviser
The Company’s Certified Adviser is DNB Carnegie Investment Bank AB
About OssDsign
OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve. The company has a strong presence in the U.S. market. OssDsign's share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
This disclosure contains information that OssDsign AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 07:00 CET on May 14th, 2025.
Datum | 2025-05-14, kl 07:00 |
Källa | Cision |
